Search
NuCana PLC
NCNAAdd to Watchlist
2.180USD
+0.200+10.10%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
9.07MMarket Cap
LossP/E TTM
More Details of NuCana PLC Company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
NuCana PLC Info
Ticker SymbolNCNA
Company nameNuCana PLC
IPO dateSep 28, 2017
CEO- -
Number of employees20
Security typeDepository Receipt
Fiscal year-endSep 28
AddressLochside House
CityEDINBURGH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeEH12 9DT
Phone4401313571111
Websitehttps://www.nucana.com/
Ticker SymbolNCNA
IPO dateSep 28, 2017
CEO- -
Company Executives of NuCana PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
+14.29%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
+75.00%
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Ian Webster
Mr. Ian Webster
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
+14.29%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
+75.00%
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Apr 16
Updated: Thu, Apr 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Glass Jacobson Wealth Advisors
0.36%
Jane Street Capital, L.L.C.
0.25%
Rhumbline Advisers Ltd. Partnership
0.09%
Sofinnova Investments, Inc
0.02%
Other
99.27%
Shareholders
Shareholders
Proportion
Glass Jacobson Wealth Advisors
0.36%
Jane Street Capital, L.L.C.
0.25%
Rhumbline Advisers Ltd. Partnership
0.09%
Sofinnova Investments, Inc
0.02%
Other
99.27%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.48%
Research Firm
0.28%
Venture Capital
0.02%
Other
99.21%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
46
32.77K
0.79%
-151.99K
2025Q4
49
170.75K
2.38%
+136.40K
2025Q3
49
156.10K
8.18%
+152.88K
2025Q2
52
554.99K
0.15%
+48.75K
2025Q1
52
492.36K
2.30%
-26.46K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Glass Jacobson Wealth Advisors
15.00K
0.36%
--
--
Dec 31, 2025
Jane Street Capital, L.L.C.
11.33K
0.27%
-1.43K
-11.23%
Dec 31, 2025
Rhumbline Advisers Ltd. Partnership
4.91K
0.12%
+4.41K
+891.72%
Dec 31, 2025
Sofinnova Investments, Inc
998.00
0.02%
+998.00
--
Feb 14, 2025
Morgan Stanley & Co. LLC
103.00
0%
+103.00
--
Dec 31, 2025
Griffith (Hugh S)
53.00
0%
--
--
Mar 18, 2026
HRK LUNIS AG
44.00
0%
--
--
Sep 30, 2024
Mellish (Martin)
7.00
0%
+1.00
+16.67%
Dec 31, 2024
Levy (Elliott M)
4.00
0%
+3.00
+300.00%
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jul 11, 2025
Merger
200→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Date
Ex-dividend Date
Type
Ratio
Jul 11, 2025
Merger
200→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
Apr 12, 2024
Merger
25→1
